Analyst RecommendationAnalyst reiterates a Buy rating for Sensei Biotherapeutics with a price target of $4, based on probability-adjusted revenue forecasts for SNS-101.
Clinical Trial ResultsSensei Biotherapeutics has reported compelling preliminary dose expansion data for solnerstotug in patients with advanced solid tumors, showing a high disease control rate.
Therapeutic Approval PotentialSNS-101 could potentially be the first anti-VISTA monoclonal antibody approved as a therapeutic agent, with an anticipated launch in 2029.